Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Non-Current Assets: 2010-2024

Historic Non-Current Assets for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $11.6 million.

  • China Pharma Holdings' Non-Current Assets rose 38.54% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year increase of 38.54%. This contributed to the annual value of $11.6 million for FY2024, which is 10.93% up from last year.
  • As of FY2024, China Pharma Holdings' Non-Current Assets stood at $11.6 million, which was up 10.93% from $10.5 million recorded in FY2023.
  • China Pharma Holdings' Non-Current Assets' 5-year high stood at $15.8 million during FY2020, with a 5-year trough of $10.5 million in FY2023.
  • Moreover, its 3-year median value for Non-Current Assets was $11.6 million (2024), whereas its average is $11.3 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first declined by 14.18% in 2021, then grew by 10.93% in 2024.
  • Over the past 5 years, China Pharma Holdings' Non-Current Assets (Yearly) stood at $15.8 million in 2020, then dropped by 14.18% to $13.6 million in 2021, then dropped by 12.81% to $11.8 million in 2022, then dropped by 11.40% to $10.5 million in 2023, then increased by 10.93% to $11.6 million in 2024.